Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation

NCT04838704 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT04838704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04838704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation
Lead sponsor
Zhejiang University
Phase
Not applicable
Overall status
Completed
Start date
April 1, 2021
Completion date
December 1, 2024
Enrollment
215 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft versus host disease